As of 2026-04-09, the Intrinsic Value of Viking Therapeutics Inc (VKTX) is -15.56 USD. This VKTX valuation is based on the model Peter Lynch Fair Value. With the current market price of 33.67 USD, the upside of Viking Therapeutics Inc is -146.22%.
Based on its market price of 33.67 USD and our intrinsic valuation, Viking Therapeutics Inc (VKTX) is overvalued by 146.22%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -15.56 - -15.56 | -15.56 | -146.22% |
| P/E | (65.67) - (68.47) | (68.63) | -303.8% |
| DDM - Stable | (17.31) - (57.89) | (37.60) | -211.7% |
| DDM - Multi | (0.25) - (0.66) | (0.37) | -101.1% |
| Market Cap (mil) | 3,890.57 |
| Beta | 1.19 |
| Outstanding shares (mil) | 115.55 |
| Enterprise Value (mil) | 3,724.76 |
| Market risk premium | 4.60% |
| Cost of Equity | 12.71% |
| Cost of Debt | 5.00% |
| WACC | 8.19% |